Shares of Kamada Ltd. (NASDAQ:KMDA - Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.64 and traded as low as $6.56. Kamada shares last traded at $6.63, with a volume of 64,599 shares trading hands.
Wall Street Analyst Weigh In
Several research firms have recently commented on KMDA. Benchmark reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Kamada in a report on Thursday, May 15th. Sidoti raised shares of Kamada to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen raised shares of Kamada from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $14.67.
Check Out Our Latest Research Report on Kamada
Kamada Price Performance
The firm has a market capitalization of $392.01 million, a PE ratio of 24.36, a P/E/G ratio of 0.97 and a beta of 0.94. The company's fifty day simple moving average is $6.57 and its 200-day simple moving average is $6.65.
Kamada (NASDAQ:KMDA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. The business had revenue of $44.02 million during the quarter, compared to analysts' expectations of $154.06 million. Kamada had a net margin of 9.92% and a return on equity of 6.30%. Analysts forecast that Kamada Ltd. will post 0.23 earnings per share for the current year.
Kamada Dividend Announcement
The firm also recently announced a -- dividend, which was paid on Monday, April 7th. Stockholders of record on Monday, March 17th were given a $0.20 dividend. The ex-dividend date was Monday, March 17th.
Institutional Investors Weigh In On Kamada
Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 1,549 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Kamada during the fourth quarter worth about $67,000. Aristides Capital LLC increased its position in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after purchasing an additional 6,850 shares during the last quarter. NewEdge Advisors LLC increased its position in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 8,260 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Kamada during the first quarter worth about $582,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
See Also
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
